Acute effects of thromboxane dual blocker (KDI-792) on different portions of lower limb blood flow-a study using doppler ultrasonography and laser doppler flowmetry in type 2 diabetic patients

Prostaglandins

Volumn 53, Issue 6, 1997, Pages 395-409

  Sone, Hirohito ^a   Okuda, Yukichi ^a   Tsurushima, Yoko ^a   Asano, Michiko ^a   Suzuki, Seiji ^a   Kawakami, Yasushi ^a   Yamashita, Kamejiro ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Diabetes millitus; Doppler flowmerry; Doppler ultrasonography; KDI 792; Thromboxane dual blocker

Indexed keywords

6 [4 (4 CHLOROPHENYLSULFONYLAMINO) 1 (3 PYRIDYLMETHYL) 2 PYRROLIDINYL] 5 HEXENOIC ACID; BERAPROST; IBUDILAST; THROMBOXANE RECEPTOR BLOCKING AGENT; THROMBOXANE SYNTHASE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FEMORAL ARTERY; FLOW RATE; HUMAN; HUMAN CELL; HUMAN TISSUE; LASER DOPPLER FLOWMETRY; LIMB BLOOD FLOW; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS;

AGED; BLOOD FLOW VELOCITY; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEUROPATHIES; ENZYME INHIBITORS; FEMALE; FOOT; HUMANS; KINETICS; LASER-DOPPLER FLOWMETRY; MALE; MIDDLE AGED; PLACEBOS; PYRIDINES; PYRROLIDINES; RECEPTORS, THROMBOXANE; THROMBOXANE-A SYNTHASE; ULTRASONOGRAPHY, DOPPLER, COLOR; ULTRASONOGRAPHY, DOPPLER, PULSED;

EID: 0030795107     PISSN: 00906980     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-6980(97)00057-9     Document Type: Article

References (37)

1. Coffman J.D. Intermittent Claudication-Be conservative. N. Engl. J . Med. 25:577-8, 1991.
2. Dyck P.J., Doll S.C. and Cromey D.C. Pathogenesis of diabetic neuropathy. Ann. Neutrol. 19:450-457, 1986.
3. Greene D.A., Lattimer S.A. and Sima A.A.F. Sorbitol, phospoinositides and sodium-potasium-ATPase in the pathogenesis of diabetic complications. N. Engl. J. Med.316:599-606, 1987.
4. Brunner D., Klinger J., Weisbort J., et al. Thromboxane, prostacyclin, beta-thromboglobin, and diabetes mellitus. Clin. Ther.6:636-42, 1984.
5. Takahashi R., Shiraki M., Morita I., Ito H., Murota S. and Orimo H. Platelet tromboxane synthesizing activity in non-insulin-dependent diabetes: correlation with diabetic retinopathy and diabetic treatment. Prostaglandins Leukot. Med. 17:149-58, 1985.
6. Kazama Y., Kanemaru Y., Noguchi T. and Onaya T. Reevaluation of circulating prostacyclin and thromboxane in diabetes. Prostaglandins Leukot. ed. 6:115-22, 1987.
7. Hamberg M., Svensson J. and Samuelsson B. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxidases. Proc. Natl. Acad. Sci. USA.72:2994-2998, 1975.
8. 2. Science. 193:1135-1137, 1976.
9. Fiddler G.I. and Lumley P. Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers. Circulation. 81(suppl I):I-69-78, 1990.
10. Gresele P., Deckmyn H., Nenci G.G. and Vermylen J. Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. Trends. Pharmacol. Sci. 12:158-63, 1991.
11. Gresele P., Arnout J., Deckmyn H., Huybrechts E., Pieters G. and Vermylen J. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. J. Clin. Invest.80:1435-45, 1987.
12. 2. Biochem. Pharmacol.33:2083-2088, 1984.
13. Gresele P., Blockmans D., Deckmyn H. and Vermylen J. Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders. J. Pharmacol. Exp. Ther.246:301-307, 1988.
14. 2 synthetase inhibitor in healthy volunteers. (Abstr. from) the 5th World Conference on Clinical Pharmacology and Therapeutics .pp. 178, 1992.
15. Sone H., Okuda Y., Mizutani M., Kawakami Y., Bannai C. and Yamashita K. The effect of nilvadipine on blood flow in the dorsal pedis artery in type 2 diabetic patients-a study using duplex Doppler ultrasonography. Postgrad. Med. J.71:613-6, 1995.
16. Nilsson G.E. A new instrument of continuous measurement of tissue blood flow by light beating spectroscopy. IEEE Trans. Biomed. Eng.27:12-19, 1980.
17. Hirata K., Nagasaka T. and Noda Y. Partitional measurement of capillary and arteriovenous anastomotic blood flow in the human finger by laser-Doppler-flowmeter. Eur. J. Appl. Physiol.57:616-621, 1988.
18. Sugenoya J. and Iwase S. Laser-Doppler flowmetry. Nihon Rinsho.50.723-728 (in Japanese, abstract in English), 1992.
19. Sugenoya J., Iwase S., Mano T. and Ogawa T. Identification of sudomotor activity in cutaneous sympathetic nerves using sweat expulsion as the effector response. Eur. J. Appl. Physiol.61:302-308, 1990.
20. Flynn M.D., Edmonds M.E., Tooke J.E. and Watkins P.J. Direct measurement of capillary blood flow in the diabetic neuropathic foot. Diabetologia.31:652-656, 1988.
21. Rendell M., Bergman T., O'Donnell G., Drobny E., Borgos J. and Bonner R. Microvascular blood flow, volume, and velocity measured by laser Doppler techniques in IDDM. Diabetes.38:819-824, 1989.
22. Irwin M., Braverman K. and Goldminz D. Correlation of laser Doppler wave patterns with underlying microvascular anatomy. J. Invest. Dermatol. 5:283-286, 1990.
23. Johnson J., Taylor W., Shepherd A. and Park M. Laser-Doppler measurement of skin blood flow: comparison with plethysmography. J. Appl. Physiol. 56:798-803, 1984.
24. 1 on the microcirculation in chronic arterial occlusive disease. J. Jpn. Col. Angiol.34:49-54 (in Japanese, abstract in English), 1994.
25. Parving H., Viberti G., Keen H., Christiansen J. and Lassen N. Hemodynamic factors in the genesis of diabetic microangiopathy. Metabolism.32:943-9, 1983.
26. Attali J.R. and Valensi P. Diabetes and hemorheology. Diabetes. Metab.16:1-6, 1990.
27. Boulton A.J.M., Scarpello J.H.B. and Ward J.D. Venous oxygenation in the diabetic neuropathic foot: Evidence of arteriovenous shunting? Diabetologia.22:6-8, 1982.
28. Sandeman D.D., Pym C.A., Green E.M., Seamark C., Shore A.C. and Tooke J.E. Microvascular vasodilation in feet of newly diagnosed non-insulin dependent diabetic patients. Br. Med. J.302:1122-3, 1991.
29. Asano M., Okuda Y., Mizutani M., et al. Effect of beraprost sodium on lower limb circulation in NIDDM patients. Evaluation by Doppler echography and laser blood flowmetry. J. Jpn. Diab. Soc.37:379-382 (in Japanese, abstract in English), 1994.
30. Sone H., Okuda Y., Asakura Y., et al. Efficacy of lower limb circulation of diabetic patients with minimally impaired baseline flow. A study using color Doppler ultrasonography and laser Doppler flowmetry. Angiology.46:699-703, 1995.
31. Hisayama T., Takayanagi I., Goromaru N. and Okamoto Y. Potentiating effect of 3-isobutyryl-2-isopropylpyrazolo-[1,5a]-pyridine (KC-404), a new cerebral vasodilator with anti-platelet activity, on prostacycline-induced increase of cyclic AMP content in platelets of rat. Gen. Pharmac.20:183-186, 1984.
32. 2 by cultured retinal endothelial cells. Life Sci.58:239-243, 1996.
33. Orzalesi G., Selleri R. and Volpato I. Fibrinolysis and inhibition of platelet aggregation by N, N′-bis(3-pycolyl)-4-methoxyisophtalamide(G-137). Prog. Chem. Fibrinolysis Thrombolysis. 1:267-9, 1975.
34. Giustina A., Bossoni S., Cimino A., et al. Picotamide, a dual TXB synthetase inhibitor and TXB receptor antagonist, reduces exercise-induced albuminuria in microalbuminuric patients with NIDDM. Diabetes.42:178-182, 1993.
35. Cocozza M., Picano T., Oliviero U., Russo N., Coto V. and Milani M. Effects of picotamide, an antithromboxane agent, on carotid atheroscrelotic evolution. A two-year, double-blind, placebo-controlled study in diabetic patients. Stroke. 26:597-601, 1995.
36. 2/prostaglandin endoperoxide receptor blockade combined in one molecule-I. Bochemical profile in vitro. Thromb. Haemost.61:35-42, 1989.
37. Hoet B., Arnout J., Van Geet C., Deckmyn H., Verhaeghe R. and Vermylen J. Rigodel, a combined thromboxane synthase inhibitor and receptor blocker, decreases elevated plasma b-thromboglobulin levels in patients with documented peripheral arterial disease. Thromb. Haemost.64:87-90, 1990.